Mental Health Kit (MHK) 2022

For an outreach population of 10’000 people for 3 months

The newly developed Mental Health Kit (MHK) 2022 is designed to treat selected mental health and neurological conditions, for outpatient care in primary health care settings and at hospital level following the WHO mhGAP Humanitarian Intervention Guide (2015), the mhGAP Intervention Guide 2.0 (2016) and WHO guidelines as described in the mhGAP Evidence Resource Centre.

For more information, consult mhGAP Evidence Resource Centre.

Composition of the MHK 2022

Download the MHK 2022 content list

Read the MHK 2022 technical note

Module 1 – Medicines for PHC

Contains essential medicines to manage selected mental health and neurological conditions in non-specialized care and needs to be handled by trained clinicians. It contains essential medicines (oral medication and injectables) to treat selected conditions such as depression, anxiety, epilepsy, schizophrenia, and bipolar disorder. This kit does not include diazepam and naloxone, both medications can be ordered separately.

To use these medicines, it is recommended to be guided by either the mhGAP Humanitarian Intervention Guide or mhGAP Intervention Guide or a similar evidence-based resource suited for the local context. All medicines in the kit are on the WHO Model EML 2023.

Health workers not specialized in psychiatry or neurology require training and supervision by specialists to handle these medicines responsibly.

Module 2 – Medicines for hospital

Contains 2 additional medicines (beyond the medicines covered in module 1 for PHC): clozapine 100mg and clozapine 25mg. Consult with a psychiatrist or available mental health specialists before the use of clozapine among those who have not responded to other antipsychotic medications at adequate doses and durations.

Only use clozapine under the supervision of a psychiatrist or available mental health specialists and only if routine laboratory monitoring of White Blood Cells count is available, due to the risk of life-threatening agranulocytosis